SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
MONTREAL, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Ropack Inc., provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries, announced the purchase of two pharmaceutical facilities in Long Island, New York. The acquisition significantly expands the company’s capabilities which will now include research and development, formulation, lab analysis and commercial and clinical manufacturing, complementing its well-established solid oral dosage packaging and clinical study distribution.
The buildings, formerly operated by Forest Laboratories, LLC, total 213,700 square feet and are a realization of Ropack Inc.’s strategic expansion plan. “It has been a longstanding goal to broaden our service offerings,” noted Yves Massicotte, President and CEO. “To establish a presence in the United States at the same time makes this acquisition ideal.” Activities in the US territory will be managed through Ropack USA Inc. Mr. Massicotte added that Ropack Inc. and Ropack USA Inc. will now be known as “Ropack Pharma Solutions.”
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” remarked Paul Dupont, Vice President of Marketing and Business Development. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
Ropack Inc., celebrating its 40th anniversary in 2016, operates four facilities in Montreal, Canada, for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets. It also is a leading Canadian clinical trial depot. It counts among its current customers many of the largest and most-respected companies in the pharmaceutical and nutraceutical industries.
Contact: Paul Dupont, VP Marketing and Business Development Ropack Pharma Solutions (514) 353-7000 [email protected] [email protected]
